Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Innovations and highlights in the Pharma industry 

Dive deep into the world of Pharma with Zamann’s Expert Blog. Our industry-leading professionals share insights on global project management, quality consultancy, digitalization, and more. Stay updated with trends and innovations transforming the Pharma industry. 

News and more

Audit trail gaps are among the top data integrity concerns during regulatory inspections. This article explores common pitfalls and how to avoid them with smart validation and QA practices.
Isolators and RABS both play critical roles in modern aseptic manufacturing, but their regulatory expectations differ significantly. FDA, EU, and ISO guidelines emphasize risk-based design, validated control measures, and procedural discipline.
Pharmaceutical firms must prioritize data integrity and robust procedures to meet FDA and EU regulatory expectations. Understanding their detailed guidelines is vital for compliance and data quality. Successfully navigating these regulations requires mastering FDA and EU requirements, including best practices
Pharmaceutical isolators have revolutionized aseptic manufacturing by offering a controlled, contamination-free environment that enhances both product safety and operator protection.
In response to the COVID-19 pandemic, the European Medicines Agency (EMA) adapted its vaccine approval processes, implementing rolling reviews and enhancing collaboration with health authorities. This post analyzes the EMA's pivotal role in granting conditional marketing authorizations for COVID-19 vaccines
As the pharmaceutical industry continues to evolve, aseptic processing must keep pace with advancing technologies. The choice between Open RABS, Closed RABS, and Isolators is crucial in ensuring sterility, regulatory compliance, and cost-effectiveness in injectable manufacturing.
Effective internal audit risk management ensures compliance, process integrity, and operational efficiency. This guide covers key risk assessment metrics, process complexity, and criticality considerations to enhance audit outcomes.
Annex 1 is part of the European Good Manufacturing Practice (EU GMP) guidelines, specifically addressing the production of sterile pharmaceutical products. Companies manufacturing injectables, ophthalmic solutions, sterile powders, and other sterile dosage forms must comply with these regulations to meet